Freenome is a biotechnology company that has pioneered the most comprehensive multiomics platform for early cancer detection with a routine blood draw, beginning with a colorectal cancer screening test.
Freenome is on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent their diseases.
Freenome was co-founded in 2014 by Charles Roberts, Gabriel Otte, Michael Otte, and Riley Ennis. The company is headquartered in South San Francisco, California.
Freenome combines its deep expertise in molecular biology with advanced computational biology and machine learning to detect disease-associated patterns among billions of circulating cell-free biomarkers.
Freenome has developed, PREEMPT CRC™ clinical trial for its blood test for colorectal cancer screening and precancerous lesion detection, advance a pipeline of blood tests for both the early detection and early intervention of additional cancers, and continue building the company’s proprietary multiomics platform.
Freenome is integrating the actionable insights through a machine learning feedback loop with healthcare providers to leverage real-world data and improve patient care through early detection.
Freenome is backed by RA Capital, Roche, Polaris Partners, Bain Capital Life Sciences, GV, Perceptive Advisors, a16z Life Sciences Growth Fund, Fidelity Management & Research Company, Janus Henderson Investors, DCVC, and others. The company $290M in new financing on Jan 11, 2022. This brings Freenome's total funding to $1.1B to date.